Browse Articles
Discover research articles across all indexed journals
Cortical reinstatement of causally related events sparks narrative insights by updating neural representation patterns
In Vivo Imaging of a Photoactivatable Platinum Prodrug by Metal-Centered Radiolabeling
Employing molecular beacons to assess in vitro transcription with single-molecule resolution
Abstract Transcription is a vital cellular process in which RNA polymerase produces messenger RNAs (mRNA) from a DNA template. Many transcription systems have been developed to reproduce this process in vitro and in the confined environment of giant unilamellar vesicles (GUVs). However, these systems and the studies employing them often use DNA concentrations significantly higher than those found in natural cells, which typically contain a single DNA copy. In this work, we introduce single-molecule in vitro transcription (smIVT) that overcomes this limitation, enabling the visualization and tracking of individual mRNA molecules both in solution and within GUVs. We achieved this by employing a molecular beacon—a quenched RNA or DNA hairpin probe that becomes fluorescent after binding to the transcript mRNA—and template DNA encoding 32 repeats of the molecular beacon binding sequence. With these, we ensured a signal-to-noise ratio sufficient to detect single mRNAs. We use smIVT to compare the performance of various commercially-available in vitro transcription kits, and to quantitatively describe single molecule transcription inside GUVs. We establish smIVT as a remarkable technique for scrutinizing in vitro transcription with single-molecule resolution.
Updated outcomes from STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial—ECOG-ACRIN EA6174.
LBA9505 Background: EA6174 (STAMP) is the first randomized phase III trial of adjuvant pembrolizumab (pembro) in resected Merkel cell carcinoma (MCC), a rare, aggressive skin cancer with high relapse risk after surgery. This abstract presents new analyses of MCC-specific outcomes and radiation therapy (RT) effects. Methods: Patients (pts) with resected stage I without a sentinel lymph node biopsy to IIIB MCC were randomized 1:1 to pembro 200 mg IV q3 weeks ×17 doses (n = 147) or standard of care (SOC) (n = 146). Randomization was stratified by stage (I/II vs III) and intended RT. Co-primary endpoints were relapse-free survival (RFS) and overall survival (OS). MCC-specific outcomes were captured as relapse due to recurrence or death due to any cause (RFS_a), and MCC-specific recurrence and death (RFS_b). Distant metastasis-free survival (DMFS) was defined as time to distant recurrence or death from MCC. 280 pts provided 80% power with one-sided type 1 error rate of 0.05 to evaluate the hazard ratio (HR) of 0.56 hierarchically (RFS before OS). One-sided p-values from the log-rank test are reported in the analysis (data as of 2/19/26, median follow-up 47 months). Results: 293 pts enrolled (67.9% male; 84.3% stage III, median age 69, > 50% accrued during the COVID-19 pandemic). Overall RFS (RFS_a) was numerically improved with pembro but not statistically significant between arms (p = 0.10). DMFS was improved in pts treated with pembro (p = .05). Significant improvement was observed in MCC-specific outcomes (RFS_b) in pts treated with pembro, with HR = 0.66 [90%CI (0.45,0.96)], resulting in 1-year and 2-year RFS_b rates of 84% [90%CI(78,88)] and 77% [90%CI(70,82)] in the pembro arm, compared with 73% [90%CI( 67,79)] and 67% [90%CI (60,74)], in the SOC arm (p = 0.032). The impact of pembro on RFS_b was maintained (p = 0.039) among the subset that received any RT (n = 131 pembro, n = 123 SOC). For pts treated concurrently with RT, pembro did not affect outcomes; however, for pts treated sequentially with RT prior to randomization (n = 68 pembro and n = 65 SOC), pembro improved RFS_a (P = 0.014), RFS_b (p = 0.009), and DMFS (p = 0.004). Conclusions: EA6174 demonstrates that pts treated with pembro experienced significantly fewer MCC-related events than pts who received SOC and that adjuvant pembro improves DMFS. RFSa may have been influenced by the average age of enrolled pts and by disruptions and morbidity associated with patient enrollment during the COVID-19 pandemic; as such RFSb may be a more accurate indicator of pembro efficacy. These findings support a meaningful impact of pembro on MCC-specific outcomes, particularly for distant relapse. Pembro may be of particular benefit when RT is delivered sequentially rather than concurrently with pembro, similar to other studies of RT and immunotherapy in solid tumors. Mature OS and MCC-specific survival data will further guide use of adjuvant immunotherapy for MCC. Clinical trial information: NCT03712605 .
Single-atom photocatalyst for click reaction
Abstract Copper(I)-catalyzed azide-alkyne cycloaddition is the most prevalent click chemistry reaction, which is widely exploited for the synthesis of diverse organic molecules. Typically, the Cu(I) catalysts are generated in situ through the chemical reduction of Cu(II) ions. Unfortunately, such homogeneous systems are considered impractical for large-scale production, and the involvement of multiple equilibria among catalysts, reductants, and substrates complicates elucidation of the catalytic process. Inspired by photosynthesis, which involves transient redox cycle of magnesium porphyrin moiety in chlorophylls, a metal complex-based strategy is proposed for light-triggered click chemistry reactions, utilizing a single-atom Cu(II)-loaded covalent organic framework as a heterogeneous catalyst, wherein the organic ligand functions as a robust scaffold and photoinitiator. Upon light irradiation, photogenerated electrons within the ligand moiety undergo ligand-to-metal charge transfer, injecting into the 3 d orbital of Cu(II) and reducing it to Cu(I) as a short-lived transient species with submicrosecond lifetime, which acts as efficient active sites for the click chemistry reaction. This controllable and robust system shows promise in photochemical cycloaddition of benzylazide and phenylacetylene, a model click chemistry reaction, achieving 95% substrate conversion and >90% triazole yield. The findings are anticipated to be broadly applicable in areas such as sustainable photolithography and polymer chemistry.
Photochemical Deracemization of Aza-1-isoindolinones: Critical Influence of Catalyst Substitution and the Nature of Its Resting State
Clinical application of AI for lung lobe segmentation and functional quantification with SPECT/CT: open-source versus custom models
Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial
Jet-induced rainfall seasonality and C4 migration over East Asia
Abstract The Neogene expansion of C 4 grasslands transformed terrestrial ecosystems with marked influence on mammalian evolution, including hominins. However, the asynchronous C 4 expansion on different continents makes it difficult to identify the environmental drivers, especially for higher latitudes. Here we show that rainfall seasonality governed extratropical Plio-Pleistocene C 4 distributions in East Asia. Rainfall oxygen isotope ratios and clumped isotope soil temperatures exhibit coupled variations on the Chinese Loess Plateau (CLP) from 7 to 2.5 million years ago, indicating more spring rain during warmer times when the subtropical westerly jet was further poleward, and more concentrated summer rain under cooler climates. We attribute these changes to meridional shifts of a summer rain band on orbital and longer timescales. The most C 4 -rich ecosystems, as identified by organic carbon δ 13 C records, tracked this summer rain band, eventually eclipsing the southern CLP margin during the late Pleistocene cooling. Our model refines the East Asian paleomonsoon concept and explains the equatorward migration of extratropical C 4 ecosystems, highlighting the tight coupling between regional rainfall seasonality and vegetation.
Iron(IV)–Cyanide Complexes Capable of Asynchronous Basicity-Driven PCET in C–H Activation upon Linkage Isomerization
Edge AI enabled MIMO MC-CDMA for 6G optimizing spectrum and energy efficiency with SIC and deep reinforcement learning
A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2−/ <i>PIK3CA</i> -mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2).
LBA1008 Background: Current standard treatment (tx) for patients (pts) with HR+/HER2-/ PIK3CA -MT advanced breast cancer (ABC) includes selective inhibitors of the PI3K/AKT/mTOR (PAM) pathway, which induce class-effect toxicities (e.g., hyperglycemia, diarrhea). Gedatolisib (geda) is a highly potent, IV-administered, comprehensive inhibitor of the PAM pathway that targets all class I PI3K isoforms, mTORC1, and mTORC2. Geda has superior preclinical potency and cytotoxicity compared to alpelisib, capivasertib, and everolimus and demonstrated activity in PIK3CA- MT and wild-type (WT) breast cancer cell lines. The randomized, open-label phase 3 VIKTORIA-1 clinical trial evaluated, in 2 cohorts by PIK3CA status, geda regimens in HR+/HER2- ABC that progressed during/after CDK4/6i + aromatase inhibitor (AI). In the PIK3CA -WT cohort, geda/fulv +/- palbo significantly improved PFS (HR vs. fulv, 0.24; 95% CI, 0.17-0.35; P<0.001, and 0.33; 95% CI, 0.24-0.48; P<0.001, respectively). We now present primary findings of the PIK3CA -MT cohort. Methods: Eligible pts had HR+/HER2- ABC with prior CDK4/6i + AI, no chemotherapy for advanced disease, no prior PAMi, measurable disease (RECIST v1.1), and HbA1c <6.5%. Pts with PIK3CA -MT disease were randomized 3:3:1 to geda/palbo/fulvestrant, alpelisib/fulv or geda/fulv in 28-day cycles of geda 180 mg IV weekly for 3 weeks on/1 week off; palbo 125 mg daily for 21 days with 7 days off; fulv 500 mg IM every 2 weeks in cycle 1 then every 4 weeks; alpelisib 300 mg per day. Response was assessed per RECIST v1.1 by blinded independent central review. The primary endpoint was PFS for the geda triplet vs. alpelisib/fulv. Secondary endpoints include PFS for the geda doublet vs. alpelisib/fulv, OS, safety, ORR, DOR, TTR, CBR, QOL, and geda PK. Statistical comparisons were performed by stratified log-rank test. Results: At data cut-off (3/09/2026; N=362), median follow-up for PFS was 11.0 mos. The trial met its primary endpoint. Median PFS for geda triplet (n=155) vs alpelisib/fulv (n=155) was 11.1 vs. 5.6 mos (HR, 0.50; 95% CI, 0.37-0.68; P<0.0001). Median PFS for the geda doublet (n=52) vs alpelisib/fulv was 11.3 vs. 5.6 mos (HR, 0.51; 95% CI, 0.33-0.79; P<0.0013). Safety was generally consistent with the individual agents, with low rates of D/C of assigned therapy due to tx-related adverse events (2.6% for geda triplet; 3.8% for geda doublet; 7.1% for alpelisib/fulv). All-grade tx-related hyperglycemia was 15.0%, 11.5%, 57.9% (grade 3: 2.6%, 0%, 13.8%), and all-grade tx-related stomatitis was 61.4%, 61.5%, and 34.2% (grade 3: 16.3%, 5.8%, and 5.3%), respectively, for geda triplet, geda doublet, and alpelisib/fulv. Conclusion: These data demonstrate that gedatolisib combination therapies offer a potential new standard of care as 2L treatment of HR+/HER2- ABC, irrespective of PIK3CA mutation status. Clinical trial information: NCT05501886 .
Individual locomotor bias drives counterclockwise motion in pedestrian crowds
One-Pot Electrochemical Synthesis of (Hydroxyamino)methanesulfonate from CO <sub>2</sub> , Nitrate/Nitrite, and Sulfite
Framework for Speciation-Gated Mass Transfer at Liquid–Liquid Interfaces
Advancing the Korpelevich method: a new approach to equilibrium problems on Hadamard manifolds
A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated <i>BRAF</i> <sup>V600E</sup> -mutant metastatic colorectal cancer.
LBA3509 Background: The BRAF V600E mutation present in approximately 10% of metastatic colorectal cancer (mCRC) cases, confers a poor prognosis with limited response to chemotherapy. Tunlametinib is a novel, oral, high-potent MEK1/2 inhibitor. Synergistic effect of tunlametinib with vemurafenib was seen in BRAF mutant non-small cell lung cancer and mCRC in the previously published phase I trial (NCT03781219.). Based on promising Phase I/II data, we have this BRAF/MEK inhibitor dual-target regimen to advance to a Phase III randomized controlled trial in this population, addressing a significant unmet need. Methods: This randomized, open-label, phase III trial (NCT06008119) enrolled patients. with BRAF V600E–mutant mCRC after ≥1 prior line of systemic therapy. Patients were randomized 2:1 to tunlametinib (12 mg BID) + vemurafenib (720 mg BID) (T+V) or investigator's choice of therapy (control). A prespecified crossover from the control to the experimental arm is allowed upon IRC-confirmed disease progression. The primary endpoint is progression-free survival (PFS) assessed by a blinded Independent Review Committee per RECIST v1.1. Secondary endpoints include overall survival (OS), objective response rate (ORR), and safety. The primary endpoint PFS analysis will use a stratified log-rank test, with the hazard ratio (HR) and its 95% confidence interval estimated using a Cox proportional hazards model. Results: As of the data cutoff date for this analysis (March 5, 2026), the full analysis set included 157 patients (105 T+V, 52 control). Based on investigator assessment (IRC assessment ongoing), median PFS was significantly prolonged with T+V versus control (4.2 months vs. 1.5 months; HR 0.374; 95% CI 0.252–0.555; P < 0.001). The ORR was 37.1% (95% CI 27.9–47.1) in the T+V group versus 7.7% (95% CI 2.1–18.5) in the control group. P<0.0001. DCR was 81.9% versus 38.5% (P < 0.0001), respectively. OS data was immature. Treatment-related grade≥3 adverse events (TRAEs) occurred in 62.0% vs 44.2% of patients, Permanent treatment discontinuation due to TRAEs occurred in 0.9% and 3.8%, respectively. Safety was consistent with that known for each agent. Conclusions: This is the first phase III randomized controlled trial to demonstrate that a BRAF/MEK inhibitor combination (tunlametinib plus vemurafenib) significantly improves PFS and ORR compared with conventional chemotherapy-based regimens in previously treated BRAF V600E–mutant mCRC, with a manageable safety profile and the added benefit of a convenient all-oral regimen. Clinical trial information: NCT06008119 .
Scaling two-dimensional semiconductor nanoribbons for high-performance electronics
Single-Molecule Visualization of Nanoscale Spatiotemporal Dynamics of Charge-Carrier-Driven Photocatalysis on 2D InSe
Assessing paver screed compaction units and their impact on asphalt quality parameters through field trials
Abstract Ensuring the durability and longevity of asphalt pavements under traffic loads requires effective compaction during paving to resist deformation and withstand environmental stresses. While previous field-based studies have addressed asphalt compaction and selected screed settings, this study specifically links tamper speed and vibratory unit speed to pre-compaction, vertical void distribution, aggregate structure, and 3D surface roughness under real paving conditions. Two field trials using an ABG P6820D paver and BOMAG BW 174 roller were conducted with an AC 16 BN asphalt mix. Laboratory analyses evaluated layer thickness, bulk density, cavity structure, and surface roughness. The findings highlight that tamper speed significantly influences layer thickness and degree of compaction, while vibratory unit speed showed no substantial effect. Vertical void distribution was highly homogeneous (> 98%) across pre-compacted areas, indicating tamper speed does not affect void distribution. Surface roughness tended to decrease with increased tamper speed, but vibratory unit speed showed no measurable benefit. No significant correlation was found between grain-to-grain distance or microstructural properties and vibratory unit speed. The study recommends minimizing adjustments to tamper speed during paving and suggests switching off the vibratory unit for the investigated AC 16 BN mixture under comparable paving conditions, provided that the required pre-compaction and surface quality are achieved. Regular monitoring of tamper wear and precise pre-paving adjustments are essential to enhance pavement quality and reduce maintenance costs.